


PCTWORLD INTELLECTUAL PROPE
International Bi

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 960602A1

(51) International Patent Classification ⁶ : A61K 31/13		A1	(11) International Publication Number: WO 96/06602
			(43) International Publication Date: 7 March 1996 (07.03.96)
(21) International Application Number: PCT/US95/10879		(74) Agents: MELOY, Sybil et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).	
(22) International Filing Date: 28 August 1995 (28.08.95)		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(30) Priority Data: PCT/US94/09466 26 August 1994 (26.08.94) WO (34) Countries for which the regional or international application was filed: US et al.		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(60) Parent Applications or Grants (63) Related by Continuation US PCT/US94/09466 (CIP) Filed on 26 August 1994 (26.08.94) US 08/112,330 (CIP) Filed on 27 August 1993 (27.08.93)			
(71) Applicant (for all designated States except US): NOVEN PHARMACEUTICALS, INC. [US/US]; 11960 S.W. 144th Street, Miami, FL 33186 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MANTELLE, Juan, A. [US/US]; 10821 S.W. 92nd Avenue, Miami, FL 33176 (US). GOLUB, Allyn, L. [US/US]; Suite 300, 18441 N.W. 2nd Avenue, Miami, FL 33169 (US).			

(54) Title: COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF δ -AMINOLEVULINIC ACID AND PHARMACEUTICAL EQUIVALENTS THEREOF**(57) Abstract**

A pharmaceutical composition of increased stability, which comprises ALA or pharmaceutical equivalents thereof and a pharmaceutically acceptable, flexible, finite carrier suitable for administration to the skin or other dermal membrane of a mammal, optionally containing a stabilizing amount of an organic weak proton donor or saccharide containing substance. The pharmaceutically acceptable carrier in solid formulation can be a skin patch, many forms and types of which are known and used in the art. It is preferable that the composition be anhydrous. The formulations appear to improve the fluorescence produced after exposing treated skin to activating light, as compared with the fluorescence produced with ALA in a fluid carrier. In particular, the pattern of fluorescence is more even and uniform over the area of application than with topical creams or salves and may provide increased fluorescence.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

COMPOSITIONS AND METHODS FOR THE
ADMINISTRATION OF δ -AMINOLEVULINIC ACID
AND PHARMACEUTICAL EQUIVALENTS THEREOF

5 Cross-Reference to Related Applications

 This application is a continuation-in-part of
PCT/US94/09466, filed August 27, 1994, which is a
continuation-in-part of Serial No. 08/112,330 filed
August 27, 1993, which is a continuation-in-part of
10 PCT/US92/01730, filed February 27, 1992, which is a
continuation-in-part of U.S. Application Serial No.
07/813,196, filed December 23, 1991, now U.S. Patent No.
5,234,957, which is a continuation-in-part of U.S. Patent
Application Serial No. 07/661,827, filed February 27,
15 1991 and now abandoned. All of the foregoing
applications are hereby incorporated by reference.

Background of the Invention

 5-Aminolevulinic acid, also referred to as δ -
aminolevulinic acid or 5-amino-4-oxopentanoic acid, is
20 referred to herein as "ALA". ALA has been known for over
40 years to be a precursor in the metabolic pathway to
heme in humans and to chlorophyll in plants. Until the
past ten years ALA has been of limited usefulness,
namely, use limited to porphyrin research. In 1984, ALA
25 was proposed for use as a photodynamic herbicide. It has
been discovered recently that ALA can be used by various
routes of administration to detect and treat certain
conditions involving rapidly metabolizing cells, namely
hyperproliferative cells. It is especially useful in the
30 treatment of malignant and non-malignant abnormal
growths.

 ALA has been administered by various routes known for
use in drug administration, but especially by topical

-2-

application to the skin and epithelium of various body cavities. Application of ALA results in the selective accumulation of clinically significant amounts of protoporphyrin IX, another precursor in the metabolic pathway to heme. Activation of protoporphyrin IX by light, depending on the wavelength of the light, will cause the protoporphyrin IX either to fluoresce (which can be used as the basis of a detection method), or to decompose (which can be used as the basis of treatment for cells that need to be removed).

ALA previously has been used in clinical testing on humans and other mammals in aqueous and non-aqueous fluid vehicles such as creams (oil in water emulsions) and lotions for application to the skin and orally for the diagnosis and treatment of skin cancers. ALA has been used in clinical studies in aqueous solution for application to the endometrial cavity.

ALA has been reported to inhibit degradation of the drug calcitonin by the nasal mucosa peptides in U.S. 5,026,825 . Preparations in the examples of that patent show a combination of calcitonin and ALA in aqueous solutions containing one or more of benzalkonium chloride, citric acid, sodium citrate, hydrochloric acid, sodium acetate and acetic acid. The organic acids and their salts appear to be used as buffers, to adjust the pH of the resulting solution to about 4.

ALA has a tendency to decompose in a wide variety of vehicles used in clinical testing including both water containing vehicles, anhydrous fluid vehicles and water and oil emulsions. In general, the lower the pH of the fluid vehicle, the more rapid the degradation. For example, addition of about 10% by weight ALA in the form the hydrochloride salt into an alkaline solution, left at room temperature, results in almost complete degradation in about one week.

-3-

Precursors or prodrugs of ALA have been reported for use in conditions similar to that as reported for ALA. The Norwegian Radium Hospital Research Foundation's PCT application No. WO 95/07077 published March 16, 1995 ("precursors") and Peng et al. Abstract, American Society of Photobiology Annual Meeting, 1995 Budapest.

The decomposition occurring with fluid preparations, such as water and ethanol, reported in the scientific literature with use of ALA patients, is sufficient to preclude the use of ALA in a product to be distributed in normal, existing channels for the supply of pharmaceuticals. Many studies have been performed without success in an attempt to stabilize ALA, with respect to extending the stability of the chemical in a fluid, including use of an aqueous solution containing certain antioxidants such as ascorbic acid and sodium bisulfite. Thus, there remains a need for a storage stable composition comprising ALA in a form suitable for administration to a patient.

Summary of the Invention

The invention relates to a pharmaceutical composition of increased stability, which comprises ALA and a pharmaceutically acceptable, flexible, finite carrier suitable for administration to the skin or other dermal membrane of a mammal, optionally containing a stabilizing amount of an organic weak proton donor or a saccharide.

The pharmaceutically acceptable carrier in solid formulation for topical delivery to the skin is desirably a skin patch, many forms and types of which are known and used in the art. It is preferable that the composition be prepared without - and essentially contain no - water. Not only are these formulations using a topical solid carrier stable after prolonged storage, but use of the formulations appear to improve the fluorescence produced

-4-

after exposing treated skin to activating light, as compared with the fluorescence produced with ALA in a fluid carrier. In particular, the pattern of fluorescence is more even and uniform over the area of application than with topical creams or salves, and may even provide increased fluorescence.

When preparing the solid formulations for topical administration, addition of a proton donor, such as a weak organic acid, can be used to increase the long-term stability of the patch. Suitable organic acids are mono- and polycarboxylic acids such as citric acid, oxalic and ascorbic acids. Weak organic acids are preferred because they are less irritating and less likely to affect the stability of the ALA. The additive also can be a saccharide. If the solid preparation contains water, it is essential to include the stabilizing amount of a proton donor or saccharide-containing substance. Anhydrous preparations, however, are preferred.

The term "stabilizing amount," when applied to the mild organic proton donor or the saccharide-containing substance of the present invention, means a concentration sufficient to prevent or minimize the degradation of ALA over the expected storage time for the composition, typically 6 months to two years. In general, this amount should be an amount at least equal in weight to the ALA present, although concentrations as high as four times the weight of ALA can be used. The saccharide-containing substance can be a complex saccharide such as starch, a gum or a polysaccharide or it can be less complex saccharide such as a monosaccharide.

The mechanism by which the solid topical formulation stabilizes the ALA is unknown. The mechanism by which the weak organic proton donor such as the weak organic acid or the saccharide-containing substance increases the stability of ALA also is unknown. It cannot be explained

-5-

merely as a reducing effect which prevents the oxidation of ALA, since other anti-oxidants, such as Vitamin E, BHT, BHA, ascorbic acid and sodium bisulfite used in an aqueous solution, were not found to be effective at increasing the stability of ALA. It is unknown whether this effect is one of protection by the saccharide-containing substance of the degradation sites on the ALA.

This invention also comprises the method of stabilizing ALA by mixing the same with an anhydrous, flexible, finite, pharmaceutically acceptable carrier for topical administration. The carrier also may comprise a weak organic proton donor or saccharide, a solid polymer, or two or more of the foregoing.

Detailed Description of the Preferred Embodiments

It now has been found that ALA can be prepared in a stable formulation for topical use by incorporation into a topical drug delivery carrier, optionally containing a mild organic proton donor or saccharide containing substance. In a preferred embodiment, the delivery carrier is contained in a patch. Use of topically acting ALA in a patch is unusual since, because of the increased costs associated with manufacture of patches. Typically, because of these costs, patches are used only for prescription drugs intended for systemic effect, but which are given topically to avoid degradation by the liver or to prolong the rate and extent of distribution.

The term a δ -aminolevulinic acid as used herein refers to ALA, pharmaceutically acceptable salts thereof and prodrugs, which are considered pharmaceutical equivalents for purposes of this invention. The nature of such salts and prodrugs are known to skilled workers in the arts. The pharmaceutically acceptable salts include, but are not limited to, acid addition salts with inorganic and organic acids as well as quaternary

-6-

ammonium salts of ALA. Suitable inorganic salts include hydrochloride, hydrobromide, sulfate, carbonate, hydrogen carbonate, hydrogen sulfate and like inorganic salts known for use with pharmacologically active substances.

5 Suitable organic acids are those mono- and polycarboxylic acids such as citric acid, ascorbic acid, oxalic acid and benzoic acid which are weak acids and can also act as a proton donor. A suitable quaternary ammonium salt is olealkonium chloride and other quaternary ammonium salts

10 that are generally recognized as safe and effective ("GRAS") under the food and drug laws for application to dermal membranes. See generally Bundgaard, H. (ed.) cited below.

The other pharmaceutically acceptable prodrugs of ALA

15 include the pharmaceutically acceptable esters - amides and other masked forms or derivatives thereof - that are metabolized in vivo to yield ALA or a solubilized form thereof.

Because of the instability of ALA in a strongly

20 acidic milieu, esterification of ALA with an aliphatic alcohol, which is normally catalyzed by a strong acid, is not preferred. Esterification may, however, be accomplished by an alternate route. For example, the amino group is protected by a carbobenzoxy group by

25 reaction with carbobenzoxy succinimide. The CBZ-ALA is reacted with a diazoalkane such as diazomethane to produce CBZ-ALA ester. The CBZ group is then removed by hydrogenolysis to produce an ALA carboxylic acid ester. The yields by such a procedure are virtually

30 quantitative.

"Pharmaceutically acceptable ester" refers to those esters which retain, upon hydrolysis of the ester bond in vivo, the biological effectiveness and properties of the carboxylic acid and are not biologically or otherwise

35 undesirable. For a description of pharmaceutically

-7-

acceptable esters as prodrugs, see Bundgaard, H., ed., (1985) Design of Prodrugs, Elsevier Science Publishers, Amsterdam. Generally, ester formation can be accomplished via conventional synthetic techniques.

5 (See, e.g., March Advanced Organic Chemistry, 3rd Ed., John Wiley & Sons, New York (1985) p. 1157 and references cited therein, and Mark et al., Encyclopedia of Chemical Technology, John Wiley & sons, New York (1980).) The ester component of the carboxylic acid ester will

10 generally comprise (i) a C1-C22 alkane that can also contain one or more double bonds and can contain branched carbon chains or (ii) a C7-C12 aromatic or heteroaromatic group. This invention also contemplates the use of those compositions which are both esters as described herein

15 and at the same time are the pharmaceutically acceptable acid addition salts thereof.

"Pharmaceutically acceptable amide" refers to those amides which retain, upon hydrolysis of the amide bond, the biological effectiveness and properties of the

20 carboxylic acid or amine and are not biologically or otherwise undesirable. For a description of pharmaceutically acceptable amides as prodrugs, see Bundgaard, H., ed., (1985) Design of Prodrugs, Elsevier Science Publishers, Amsterdam. These amides are

25 typically formed from the corresponding carboxylic acid and an amine. Generally, amide formation can be accomplished via conventional synthetic techniques. (See e.g., March Advanced Organic Chemistry, 3rd Ed., John Wiley & Sons, New York (1985) p. 1152, and Mark et al.,

30 Encyclopedia of Chemical Technology, John Wiley & Sons, New York (1980).) This invention also contemplates the use of those compositions which are both amides as described herein and at the same time are the pharmaceutically acceptable acid addition salts thereof.

35 The stability of ALA may be increased by incorporating it into a solid, pharmaceutically

-8-

acceptable carrier, preferably a topical carrier and more preferably in an anhydrous adhesive topical carrier. The solid carrier can optionally contain an organic weak proton donor such as a weak organic acid, or a
5 saccharide-containing substance.

The term "pharmaceutically acceptable carrier" used here with reference to topical administration refers to the wide variety of carriers known for use for application to the skin or body cavity to a dermal
10 membrane. Such carriers are well known in the art.

The term "organic weak proton donor" used here refers to an organic substance known to function as a weak acid which does not, at the same time, degrade the ALA. Whether the organic substance will degrade the ALA can be
15 determined easily by placing the substance at the concentration intended for use with the ALA, then analyzing for residual ALA. Suitable organic weak proton donors are organic weak acids such as mono- and polycarboxylic acids such as citric acid, oxalic acid,
20 ascorbic acid and benzoic acid. Other suitable stabilizers are gums such as guar gum, xanthan gum, karaya gum, British gum, starch gum, tragacanth gum, pectin gum and derivatives thereof, saccharides such as complex saccharides such as cellulose, polysaccharides
25 such as dextran and dextrin, and monosaccharides such as dextrose, fructose, maltose, D-glucose and L-glucose. Corn syrup, composed of dextrin and glucose is particularly useful, but its use is limited by the fact that it generally contains water.

30 The solid topical forms of the present invention include all the known types of devices, including both the adhesive matrix and reservoir devices. Matrix devices are preferred because the minimization of the number of layers of the device results in ease of
35 preparation. The matrix devices are prepared by methods

-9-

known in the art. The most convenient form for manufacture of a matrix device is one in which the ALA is dispersed in a pressure sensitive adhesive. The matrix devices are preferably prepared using commercially
5 supplied organic solvents containing the polymer. The additional ingredients are added to the mixture and then the solvents are removed to form the patch. This avoids the use of or inclusion of water in the composition and the need to perform a cross-linking step after the
10 mixing, such as is necessary for emulsion polymerization.

Pressure sensitive adhesives useful in preparing the preferred topical compositions include a wide variety of polymeric adhesives including pharmaceutically acceptable acrylics, vinyl acetate, silicone and synthetic or
15 natural rubber adhesives and mixtures thereof. Acrylic adhesives include Gelva adhesives GMS 1430, 788 available from Monsanto Co. and various Durotak adhesives such as 87-2852 manufactured by National Starch. Vinylacetate adhesives including Flexbond 149 and 150 from Air
20 Products are of limited usefulness because they contain water. Rubber based adhesives such as the Morstiks from Morton Thiokol, Ins. or Vistanex manufactured by Exxon Chemicals can be used. Numerous silicone based adhesives are available from Dow-Corning. These and other pressure
25 sensitive adhesives suitable for topical application will be apparent to one skilled in the art.

For adhesive matrix devices, the polymer blend is applied to a suitable backing material impermeable to the drug or the other components of the polymer matrix. The
30 backing materials, which are preferably water resistant, and occlusive or non-occlusive, can be selected from such material as foam, metal foil, polyester, low density polyethylene, copolymers of vinyl chloride and polyvinylidene chloride and laminates thereof.

-10-

Where the topical device is a reservoir-type device, the ALA in a solvent, preferably in a non-aqueous solvent such as an alkanediol or an organic acid such as citric acid is used to fill the reservoir. About 0.1 to about 2%, preferably about 0.5% of a gelling agent such as hydroxypropyl cellulose, can be added to form a gel. The solution or gel is retained in the reservoir by a suitable rate-controlling membrane such as an ethylene-vinyl acetate copolymer membrane, which membrane preferably has a face layer of a pressure sensitive adhesive as described above. Backing materials are similar to those described above for matrix devices.

Both adhesive matrix and reservoir devices contain a release liner impermeable to the drug and any solvents present in the system in order to protect the adhesive layer until the patch is to be applied to the skin. Typical materials for release liners are polyester, polyethylene, and polyethylene coated paper, preferably silicon-coated to facilitate removal.

The adhesive matrices of the present invention contain 0.5 to 50% ALA by weight, preferably 5 to 20%, and most preferably 10 to 20%; 50 to 95% adhesive, preferably 60 to 90% and more preferably 70 to 90%. An optional carrier and may contain from 0 to 40% by weight of other components, such as a proton donor, penetration enhancer and other substances known for use in transdermal formulations. Since the ALA in the solid formulation is used for a topical effect, there is in fact no maximum limitation as to the amount of ALA that can be used in the patch except to the extent that the adhesiveness or stability of the patch is affected.

Methods for preparing adhesive matrix devices are known in the art. A preferred method for preparing adhesive matrix topical devices of the present invention comprises coating a thin layer of the adhesive polymer

-11-

containing the ALA optionally in an anhydrous solvent and optionally containing a mild organic proton donor such as saccharide-containing substance or a mild organic acid onto the material to be used as a release liner, cross-
5 linking the polymer blend in the case of an adhesive to be cross-linked, drying the release liner containing the polymer mixture, then laminating the backing material to the resultant adhesive layer. The preferred proton donor for the ALA is any liquid material or a saccharide-
10 containing substance or an organic acid such as citric acid in a non-aqueous solvent. Additional substances which increase the passage of the drug into the skin also can be added. Suitable sized patches can then be cut out and the patches preferably sealed in protective pouches.

15 The layer of polymer mixture cast on the release liner according to the preferred method of this invention is about 5 mils to about 30 mils thick. The coated layer is preferably dried at a temperature of about 80 degrees Centigrade. One mil = 0.0254 mm.

20 The size of the topical device of the present invention depends on the dose of ALA to be utilized, with the preferred patch area being about 2.5 to 20 cm², preferably 5 to 15 cm². The preferred delivery rate for ALA is at least 0.1 µg. per cm² per hour, giving a
25 preferred daily dosage of at least 0.25 mg. per day applied to the area of the skin to be diagnosed or treated for about 2-48 hours. The optimum concentration of ALA in a patch is at least 0.1-3.0 mg. per cm².

As a minimum, the topical device must contain a
30 pharmacologically effective amount of ALA. Generally, this is at least 0.25 mg. The duration of application is that period sufficient to achieve ALA penetration into the diseased tissue and that permits high localized concentrations of protoporphyrin IX resulting from the
35 conversion of ALA. This period may be about 3-24 hours

-12-

and, preferably, is 12-16 hours. The effective amount and duration will vary depending on the nature of the lesion and may be determined empirically by those skilled in the art by testing localized fluorescence of the lesion after administration. If fluorescence is insufficient, longer application or higher ALA concentrations may be used.

Topical ALA photodynamic therapy (ALA PDT[™]) involves the exposure of the ALA-treated lesion with light. A suitable wavelength is 400 nm, 634 nm or 600-700 nm, at an intensity of 10-100 milliwatts per centimeter squared (mW/cm²) to provide a light dose of 10-100 Joules/cm². Exposure time may vary from 3 to 30 minutes, but preferably is about 10 minutes. Upon exposure, activation of protoporphyrin IX leads to *in situ* breakdown of protoporphyrin IX and the generation of singlet oxygen, leading to the destruction of diseased cells.

The target tissues for which the present invention may be used are any visible, cutaneous lesion or other undesired rapidly growing cells. In particular, these include, but are not limited to, neoplastic, aplastic and hyperplastic skin conditions such as basal cell carcinoma, actinic keratosis, psoriasis and similar conditions.

-13-

Example 1

The following table shows typical adhesive matrix formulations of this invention. In this table GMS means Gelva multipolymer system, and the percentages shown are percentages by weight:

Gelva Multipolymer Solution = Acrylic Adhesive = GMS

10

	%w/w	%w/w	%w/w	%w/w	%w/w	%w/w	%w/w	%w/w
GMS 1430	80	90	80	70	65	80		
ALA	10	10	10	10	10	10		
Citric Acid	10	—	5	10	5	—		
Corn Syrup	—	—	5	10	20	10		
GMS 788	80	90	80	70	60	50	50	
ALA	10	10	10	10	10	10	10	
Citric Acid	10	—	5	10	—	—	10	
Corn Syrup	—	—	5	10	30	40	30	
GMS 788	40	80	70	35	30	25	25	45
GMS 1430	40	5	5	35	30	25	25	45
ALA	10	10	10	10	10	10	10	10
Citric Acid	10	5	5	10	—	—	10	—
Corn Syrup	—	—	10	10	30	40	30	—
Duro-Tak 87-2852	80	80	50	50	60	70	70	90
ALA	10	10	10	10	10	10	10	10
Citric Acid	10	—	—	10	10	5	—	—
Corn Syrup	—	10	40	30	20	15	20	—

15

20

-14-

Example 2

In the following example the ALA, propylene glycol, lecithin and glycerin are blended at about 70 to 90°C until all the drug is dissolved. The solution is then cooled to about 20 to 35°C prior to adding the karaya gum. Once the karaya gum is added, the final composition is applied to a suitable backing material such as a non-woven polyester film (for example, the film sold under the trademark Sontara 8100, manufactured by DuPont de Nemours, Wilmington, DE) and warmed to about 100°C to accelerate the formation of the gel into its final, finite form.

5-Aminolevulinic Acid

	%w/w	%w/w	%w/w	%w/w	%w/w
ALA	2	5	10	15	20
Solvent (dipropylene glycol)	10	10	15	15	15
Solvent (Oleic acid)	10	10	10	10	10
Solvent (glycerin)	30	30	20	20	30
Solvent (isocetyl alcohol)	--	--	10	10	--
Bioadhesive (karaya gum)	30	30	20	20	30
Bioadhesive (xantham gum)	--	--	10	10	--
Binder (lecithin)	18	15	10	10	--

-15-

Example 3

A thirty-two year old female is diagnosed with basal cell carcinoma. A single lesion is evident on her right forearm covering approximately 22 mm², and topical aminolevulinic acid photodynamic therapy (ALA PDT™) is prescribed.

A 5 cm² topical patch containing 10% (w/w) ALA, made according to Example 1 or 2, is applied to the lesion. The patch is left in place for 18 hours, which is sufficient to permit adequate penetration of ALA into the lesion and for the formation of protoporphyrin IX ("PpIX"), the active end product of topical ALA administration. After the patch is removed, the lesion is wiped with an alcohol swab to remove any residual adhesive.

The lesion is then exposed to activating UV light using a conventional Woods lamp to determine if the fluorescence levels, and hence the PpIX levels, are sufficient. Finding the levels suitable, the lesion is then exposed to a 634 nm wavelength light source at 100 mW/cm² for 15 minutes.

Within 30 minutes, a localized reaction is observed, characterized by the rapid onset of redness, erythema and edema at the treatment site. During the next several days, necrosis of the destroyed lesional cells ensues, resulting in the formation of a burn-like scab over the former lesion. During the next six weeks, normal healing of the treated tissue and restoration of intact skin is observed.

The foregoing examples are illustrative embodiments of the invention and are merely exemplary. A person skilled in the art may make variations and modification without departing from the spirit and scope of the

-16-

invention. All such modifications and variations are intended to be included within the scope of the invention as described in this specification and the appended claims.

-17-

What Is Claimed Is

1. A pharmaceutical composition comprising:
 - (i) a therapeutically effective amount of a δ -aminolevulinic acid or a pharmaceutical equivalent thereof; and
 - (ii) a pharmaceutically acceptable, flexible, finite carrier for dermal application.
2. The composition of claim 1, wherein said pharmaceutical equivalent is an ester of δ -aminolevulinic acid.
3. The composition of claim 1, wherein said pharmaceutical equivalent is an amide of δ -aminolevulinic acid.
4. The pharmaceutical composition of claim 1, wherein said δ -aminolevulinic acid or pharmaceutical equivalent thereof is dispersed throughout the carrier.
5. The pharmaceutical composition of claim 1, wherein said carrier is an adhesive.
6. The pharmaceutical composition of claim 5, wherein said adhesive is a pressure-sensitive adhesive.
7. The pharmaceutical composition of claim 6, wherein said pressure sensitive adhesive is a bio-adhesive.
8. The pharmaceutical composition of claim 6, wherein said pressure sensitive adhesive is a polymeric adhesive selected from the group consisting of an acrylic, a silicone-based adhesive, a vinyl acetate adhesive and a natural or synthetic rubber-based adhesive, or mixtures thereof.

-18-

9. The pharmaceutical composition of claim 5, wherein said adhesive additionally contains a stabilizing amount of a saccharide.

10. The pharmaceutical composition of claim 9, wherein said saccharide is selected from the group consisting of dextrans, dextrans, polysaccharides, disaccharides and monosaccharides.

11. The pharmaceutical composition of claim 10, wherein said monosaccharide is selected from the group consisting of dextrose, fructose, D-glucose and L-glucose.

12. The pharmaceutical composition of claim 9, wherein said saccharide is a mixture of a substance selected from the group consisting of dextrans, dextrans and monosaccharides.

13. The pharmaceutical composition of claim 5, wherein said adhesive additionally contains a stabilizing amount of an organic weak proton donor.

14. The pharmaceutical composition of claim 13, wherein said organic weak proton donor is a carboxylic acid.

15. The pharmaceutical composition of claim 14 wherein said carboxylic acid is selected from the group consisting of citric acid, oxalic acid, ascorbic acid and benzoic acid.

16. The pharmaceutical composition of claim 13, wherein said composition is substantially anhydrous.

17. The pharmaceutical composition of claim 13 comprising, in weight percentages, about 0.5% to about

-19-

50% δ -aminolevulinic acid, and about 10% to about 95% of an adhesive.

18. A method of stabilizing δ -aminolevulinic acid or a pharmaceutical equivalent thereof, comprising mixing said δ -aminolevulinic acid or said pharmaceutical equivalent thereof with an anhydrous, flexible, finite pharmaceutically acceptable carrier suitable for topical administration.

19. The method of claim 18, wherein a weak organic proton donor is also added to the mixture.

20. The method of claim 19, wherein said weak organic proton donor is a carboxylic acid.

21. The method of claim 18, wherein said carrier is an adhesive.

22. The method of claim 21, wherein said adhesive is a pressure sensitive adhesive.

23. The method of claim 21, wherein said adhesive is selected from the group consisting of bioadhesives and polymeric adhesives.

24. The method of claim 23, wherein said polymeric adhesive is selected from the group consisting of an acrylic, a silicone-based adhesive, a vinyl acetate adhesive, and a natural or synthetic rubber-based adhesive, or mixtures thereof.

25. The use of δ -aminolevulinic acid or a pharmaceutical equivalent thereof for the preparation of a transdermal drug delivery device comprising a therapeutically effective amount of said δ -aminolevulinic acid or pharmaceutical equivalent thereof in a flexible

-20-

finite carrier for application to skin or other dermal
membrane of a mammal.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10879

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/13.

US CL :514/671

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/671

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US, A, 5,369,142 (CULBERTSON ET AL.) 29 November 1994, column 4, lines 27 TO 45.	1-25

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 DECEMBER 1995

Date of mailing of the international search report

26 DEC 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

THEODORE J. CRIARES

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235